Biotech

Inside the discoveries, personalities, and deals driving drug development. Sign up for the Readout newsletter here.

transmission electron micrograph covid19
Adam's Take

Biotech, bracing for widespread coronavirus fallout, hopes for the best and prepares for the worst

By Adam Feuerstein

FDA through the window
Biotech

FDA rejects Intarcia’s diabetes implant for a second time

By Kate Sheridan

China flags
Biotech

Global companies expand the reach of their cancer drugs in China

By Jonathan Chan

closed doors
Biotech

Pace of medical conference shutdowns is accelerating as the coronavirus outbreak spreads

By Adam Feuerstein

Health

Top Biogen execs were present at meeting where attendees had Covid-19

By Kate Sheridan, Adam Feuerstein, and Matthew Herper

Gene therapy
Biotech

Gene and cell therapies continue growth in patients, financing, and costs

By Andrew Joseph

Genetic Frontiers Gene Editing Blindness
In the Lab

In its first use inside the human body, CRISPR genome editing tested as blindness therapy

By Associated Press

gene therapy
Biotech

This biotech went public during the stock market’s worst week since 2008

By Kate Sheridan

Adam's Take

TG Therapeutics cops to another blood cancer drug trial delay, as excuses wear thin

By Adam Feuerstein

Thermo Fisher Scientific
Biotech

Thermo Fisher buys Dutch diagnostics company for $11.5 billion

By Jonathan Saltzman — Boston Globe

Vaccine glass bottles
Biotech

A detailed guide to the coronavirus drugs and vaccines in development

By Damian Garde

Biotech

Cancer biotech gets another new name (now it’s called Xilio) and more than $100 million

By Jonathan Saltzman — Boston Globe

Daniel O'Day
Biotech

CEO Daniel O’Day explains why Gilead paid $4.9 billion for Forty Seven

By Matthew Herper

BUSINESS TEAM
Biotech

Karyopharm to seek expanded use of multiple myeloma drug following positive clinical trial

By Adam Feuerstein

Todd Mercer clinical trials
Biotech

Turned away from five clinical trials, a cancer patient waits for one that will take him

By Rebecca Robbins, Damian Garde, and Adam Feuerstein

Sangamo zinc fingers illo
Biotech

Biogen, Sangamo partner to develop genome-editing therapies for Alzheimer’s and Parkinson’s disease

By Adam Feuerstein

Alzheimer's Tau imaging
In the Lab

They have ‘Alzheimer’s brains’ but no symptoms. A new wave of drug developers wants to know why

By Sharon Begley

Adam's Take

Allakos is running clinical trials in reverse, critics say, raising questions about its digestive disease drug

By Adam Feuerstein

Meghan Waldron is a freshman at Emerson College with progeria, one of the world's rarest diseases.
Biotech

College student with disease that causes premature aging is heartened by medical advances

By Jonathan Saltzman — Boston Globe

Eye - for spark
Biotech

Safety concerns regarding Novartis’ new eye drug boost Regeneron stock

By Matthew Herper

Pharma

Sanofi to start pharmaceutical ingredients company, which it says may avert future shortages

By Matthew Herper

Vivitrol Opioids
Biotech

Alkermes sued over death of man who overdosed after taking addiction treatment Vivitrol

By Felice J. Freyer — Boston Globe

Graph Vs Host Disease
Biotech

With strong data on lead drug, Kadmon and CEO Harlan Waksal plot their redemption

By Adam Feuerstein

Clogged Artery
Biotech

After 21-year journey, Esperion to test market for a cholesterol pill that is less expensive than some competitors

By Matthew Herper

Cervical cancer cells
Biotech

Antigen-based metric could better predict which patients benefit from immunotherapy, study says

By Shafaq Zia

office cubicles
Biotech

In a cramped Kendall Square, biotech startups sublet desks and squeeze into shared labs

By Kate Sheridan

Three vials
Pharma

Roche confirms departure of gene therapy pioneer Kathy High

By Matthew Herper

colored DNA sequencing
Health Tech

FDA names genes that may interact with specific drugs, offering clarity to genetic testing industry

By Rebecca Robbins

Frank Reynolds, CEO of PixarBio, sentenced to 7 years for defrauding investors
Biotech

Biotech founder who said his painkiller would replace opioids sentenced to 7 years in prison

By Jonathan Saltzman — Boston Globe

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy